Event Schedules, Survey Findings, Regulatory Filings, and Market Activity - Research Reports on Amgen, Biogen Idec, Salix, Covidien and Shire

NEW YORK, September 15, 2014 /PRNewswire/ --

Today, Analysts Review released its research reports regarding Amgen Inc. (NASDAQ: AMGN), Biogen Idec Inc. (NASDAQ: BIIB), Salix Pharmaceuticals Ltd. (NASDAQ: SLXP), Covidien plc (NYSE: COV) and Shire plc (NASDAQ: SHPG). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6458-100free.

--
Amgen Inc. Research Reports
On September 10, 2014, Amgen Inc. (Amgen) announced that it will present data from multiple Prolia® (denosumab) and romosozumab study analyses at the American Society for Bone and Mineral Research (ASBMR) 2014 Annual Meeting, which is being held in Houston from September 12-15, 2014. Amgen said that Prolia data consist of 18 abstracts, including several exploratory analyses evaluating eight years of Prolia therapy from the open-label extension study of the pivotal Phase 3 fracture trial. "Given that more than 200 million women worldwide have osteoporosis, and many of these have experienced a fracture, additional therapies are needed to help manage the continuum of the disease," said Sean E. Harper, M.D., Executive Vice President of Research and Development at Amgen. Harper added, "Limited data exists on the risks and benefits of the long-term treatment of osteoporosis, and we're excited to help address this gap with the large body of Prolia data we will present at this year's meeting." The full research reports on Amgen are available to download free of charge at:

http://www.analystsreview.com/Sep-15-2014/AMGN/report.pdf

--
Biogen Idec Inc. Research Reports
On September 10, 2014, Biogen Idec Inc. (Biogen Idec) reported the findings of an international survey which revealed that multiple sclerosis (MS) patients and neurologists are struggling to discuss key MS symptoms which could potentially impact disease management and patient quality of life. The survey, commissioned by Biogen Idec and conducted online by Harris Poll, was developed in partnership with the State of MS Consortium. The survey found that there were differences in the perceptions of MS patients and neurologists when discussing symptoms, even as they both recognize the importance of communication. "Our goal with this survey was to better understand the needs of the patient and the physician, and through that understanding bring a new awareness to the importance of a comprehensive dialogue about MS," said Gilmore O'Neill, Vice President, Multiple Sclerosis Research and Development, Biogen Idec. Last month, Biogen Idec's PLEGRIDYTM (peginterferon beta-1a) received FDA approval for treatment of people with relapsing forms of multiple sclerosis. The full research reports on Biogen Idec are available to download free of charge at:

http://www.analystsreview.com/Sep-15-2014/BIIB/report.pdf

--
Salix Pharmaceuticals Ltd. Research Reports
On September 2, 2014, Salix Pharmaceuticals Ltd. (Salix) announced that it has submitted its response to the U.S. FDA's Complete Response Letter (CRL) dated March 7, 2011, regarding the Company's supplemental New Drug Application or sNDA for XIFAXAN® 550 mg tablets for the proposed indication of the treatment of irritable bowel syndrome with diarrhea or IBS-D. According to the Company, the FDA will have six months to respond back to the Company's response. "We are pleased that the outcome of TARGET 3 provides both prospective controlled data to support the efficacy and safety of repeat treatment with rifaximin," stated Bill Forbes, PharmD, Executive Vice President, Medical, Research and Development and Chief Development Officer, Salix. During its original review of Salix's sNDA, the FDA had determined it is important in condition like IBS to have information about how a product that is intended for short course administration should be administered beyond the first cycle of use once symptoms reappear. The full research reports on Salix are available to download free of charge at:

http://www.analystsreview.com/Sep-15-2014/SLXP/report.pdf

--
Covidien plc Research Reports
On September 10, 2014, the stock of Covidien plc (Covidien) continued its northward journey for the fourth consecutive session and ended higher by 0.47% at $91.07. The stock has a 52-week high of $92.68. During the session, the Company's stock opened at $90.88, and fluctuated in the range of $90.31 - $91.40, with a total of 2.77 million shares changing hands. Over the last one month, shares in Covidien have increased by 7.51%, compared to the S&P 500 index which rose 3.03% during that period. Also, the stock closed above its 50-day and 200-day moving averages of $88.10 and $75.21, respectively. The full research reports on Covidien are available to download free of charge at:

http://www.analystsreview.com/Sep-15-2014/COV/report.pdf

--
Shire plc Research Reports
Shire plc (Shire) posted on its Investor Relations website that it will participate in the Bank of America Merrill Lynch Global Health Care Conference on September 19, 2014. The full research reports on Shire are available to download free of charge at:

http://www.analystsreview.com/Sep-15-2014/SHPG/report.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review